<p>Disc Medicine, Inc.（纳斯达克代码：IRON - 获取免费报告）内部人士 William Jacob Savage 于 12 月 15 日（星期一）出售了该公司 13,093 股股票。股票的平均售价为 91.22 美元，总交易额为 1,194,343.46 美元。出售完成后，该内部人士在公司持有 75,702 股，价值 6,905,536.44 美元。这代表其持股比例减少了 14.75%。该交易已在美国证券交易委员会的备案中披露，具体信息可通过此链接查看。</p>
<p>获取 <strong>Disc Medicine</strong> 警报：</p>
<h2>Disc Medicine 股票下跌 0.6%</h2>
<p>周二交易时段，纳斯达克 IRON 的股票下跌 0.53 美元，报 91.47 美元。该股票交易量为 639,414 股，而其平均交易量为 536,679 股。Disc Medicine, Inc.的 12 个月最低价为 30.82 美元，最高价为 99.50 美元。该公司的 50 日移动平均价格为 86.99 美元，200 日移动平均价格为 68.22 美元。公司的速动比率为 23.45，流动比率为 23.45，债务与股本比率为 0.05。公司的市值为 34.5 亿美元，市盈率为-17.10，贝塔系数为 0.87。</p>
<p>Disc Medicine（纳斯达克代码：IRON - 获取免费报告）最近一次公布财报是在 11 月 6 日（星期四）。公司报告季度每股收益为-1.77 美元，低于市场共识预期的-1.48 美元，差额为-0.29 美元。卖方分析师平均预计 Disc Medicine, Inc.在当前年度的每股收益为-4.07 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>几家券商最近对 IRON 进行了评估。摩根士丹利在 10 月 30 日的研究报告中将 Disc Medicine 的目标价从 90.00 美元上调至 115.00 美元，并给予该股票 “增持” 评级。Stifel Nicolaus 在 11 月 3 日的报告中开始覆盖 Disc Medicine，给予 “买入” 评级和 125.00 美元的目标价。National Bankshares 在 10 月 17 日的报告中对 Disc Medicine 的股票设定了 153.00 美元的目标价。Cantor Fitzgerald 在 10 月 17 日的研究报告中将 Disc Medicine 的目标价从 132.00 美元上调至 153.00 美元，并给予 “增持” 评级。最后，Wedbush 在 10 月 17 日的研究报告中将 Disc Medicine 的目标价从 90.00 美元上调至 110.00 美元，并给予 “跑赢大盘” 评级。一位投资分析师对该股票给予了强烈买入评级，十位分析师给予买入评级，一位分析师给予卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 119.00 美元。</p>
<p><strong>获取我们最新的 IRON 股票分析</strong></p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者最近调整了对该公司的持股。Aster Capital Management DIFC Ltd 在第三季度收购了 Disc Medicine 的新股份，价值约 38,000 美元。CWM LLC 在第二季度将其在 Disc Medicine 的持股增加了 213.5%。CWM LLC 目前持有 1,044 股该公司的股票，价值 55,000 美元，此前在上个季度又购买了 711 股。Avanza Fonder AB 在第二季度收购了 Disc Medicine 的新股份，价值 57,000 美元。Mirae Asset Global Investments Co. Ltd.在第二季度将其在 Disc Medicine 的持股增加了 15.6%。Mirae Asset Global Investments Co. Ltd.目前持有 1,338 股该公司的股票，价值 71,000 美元，此前在此期间又购买了 181 股。最后，Ameritas Investment Partners Inc.在第二季度将其在 Disc Medicine 的持股增加了 8.9%。Ameritas Investment Partners Inc.目前持有 2,515 股该公司的股票，价值 133,000 美元，此前在上个季度又购买了 206 股。当前 83.70% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Disc Medicine</h2>
<p>（获取免费报告）</p>
<p>Disc Medicine, Inc.及其子公司是一家临床阶段的生物制药公司，专注于发现、开发和商业化针对美国严重血液疾病患者的新治疗方案。该公司已组建了一系列临床和临床前产品候选者，旨在改变与红细胞形成和功能相关的基本生物途径，主要是血红素生物合成和铁稳态。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Disc Medicine</li>
<li>公用事业股票解析 – 如何以及为何投资公用事业</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个明智的买入</li>
<li>投资者如何识别并成功交易缺口下跌股票</li>
<li>RTX 因国防订单激增而飙升至历史新高</li>
<li>三大医疗股息股票值得买入和持有</li>
<li>聪明资金正在购买汽车供应商，而不是汽车品牌</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Disc Medicine 吗？</h2>
<p>在考虑 Disc Medicine 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Disc Medicine 并不在名单上。</p>
<p>虽然 Disc Medicine 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

IRON

<p>Disc Medicine 的内部人士 William Jacob Savage 出售了 13,093 股，每股售价为 91.22 美元，总计 1,194,343.46 美元。此次出售使他的持股减少了 14.75%，剩余 75,702 股，价值 6,905,536.44 美元。该交易已向美国证券交易委员会（SEC）披露。Disc Medicine 的股票下跌了 0.6%，报 91.47 美元。分析师对该股票给予了 “适度买入” 的评级，目标价共识为 119.00 美元。机构投资者正在调整他们在公司的持股</p>

<p>Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider William Jacob Savage sold 13,093 shares of the firm's stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $91.22, for a total transaction of $1,194,343.46. Following the completion of the sale, the insider owned 75,702 shares in the company, valued at $6,905,536.44. This represents a 14.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.</p>
<div class="lb-trans"><p>Disc Medicine, Inc.（纳斯达克代码：IRON - 获取免费报告）内部人士 William Jacob Savage 于 12 月 15 日（星期一）出售了该公司 13,093 股股票。股票的平均售价为 91.22 美元，总交易额为 1,194,343.46 美元。出售完成后，该内部人士在公司持有 75,702 股，价值 6,905,536.44 美元。这代表其持股比例减少了 14.75%。该交易已在美国证券交易委员会的备案中披露，具体信息可通过此链接查看。</p>
</div><p>Get <strong>Disc Medicine</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Disc Medicine</strong> 警报：</p>
</div><h2>Disc Medicine Stock Down 0.6%</h2>
<div class="lb-trans"><h2>Disc Medicine 股票下跌 0.6%</h2>
</div><p>Shares of NASDAQ IRON traded down $0.53 during trading hours on Tuesday, hitting $91.47. 639,414 shares of the stock were exchanged, compared to its average volume of 536,679. Disc Medicine, Inc. has a 12 month low of $30.82 and a 12 month high of $99.50. The firm has a fifty day moving average price of $86.99 and a 200-day moving average price of $68.22. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The company has a market cap of $3.45 billion, a PE ratio of -17.10 and a beta of 0.87.</p>
<div class="lb-trans"><p>周二交易时段，纳斯达克 IRON 的股票下跌 0.53 美元，报 91.47 美元。该股票交易量为 639,414 股，而其平均交易量为 536,679 股。Disc Medicine, Inc.的 12 个月最低价为 30.82 美元，最高价为 99.50 美元。该公司的 50 日移动平均价格为 86.99 美元，200 日移动平均价格为 68.22 美元。公司的速动比率为 23.45，流动比率为 23.45，债务与股本比率为 0.05。公司的市值为 34.5 亿美元，市盈率为-17.10，贝塔系数为 0.87。</p>
</div><p>Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.29). On average, sell-side analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.</p>
<div class="lb-trans"><p>Disc Medicine（纳斯达克代码：IRON - 获取免费报告）最近一次公布财报是在 11 月 6 日（星期四）。公司报告季度每股收益为-1.77 美元，低于市场共识预期的-1.48 美元，差额为-0.29 美元。卖方分析师平均预计 Disc Medicine, Inc.在当前年度的每股收益为-4.07 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several brokerages recently weighed in on IRON. Morgan Stanley boosted their target price on Disc Medicine from $90.00 to $115.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, October 30th. Stifel Nicolaus initiated coverage on Disc Medicine in a report on Monday, November 3rd. They issued a &#34;buy&#34; rating and a $125.00 price target for the company. National Bankshares set a $153.00 price objective on shares of Disc Medicine in a report on Friday, October 17th. Cantor Fitzgerald lifted their target price on shares of Disc Medicine from $132.00 to $153.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, October 17th. Finally, Wedbush boosted their target price on shares of Disc Medicine from $90.00 to $110.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $119.00.</p>
<div class="lb-trans"><p>几家券商最近对 IRON 进行了评估。摩根士丹利在 10 月 30 日的研究报告中将 Disc Medicine 的目标价从 90.00 美元上调至 115.00 美元，并给予该股票 “增持” 评级。Stifel Nicolaus 在 11 月 3 日的报告中开始覆盖 Disc Medicine，给予 “买入” 评级和 125.00 美元的目标价。National Bankshares 在 10 月 17 日的报告中对 Disc Medicine 的股票设定了 153.00 美元的目标价。Cantor Fitzgerald 在 10 月 17 日的研究报告中将 Disc Medicine 的目标价从 132.00 美元上调至 153.00 美元，并给予 “增持” 评级。最后，Wedbush 在 10 月 17 日的研究报告中将 Disc Medicine 的目标价从 90.00 美元上调至 110.00 美元，并给予 “跑赢大盘” 评级。一位投资分析师对该股票给予了强烈买入评级，十位分析师给予买入评级，一位分析师给予卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 119.00 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on IRON</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 IRON 股票分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors have recently modified their holdings of the company. Aster Capital Management DIFC Ltd acquired a new stake in shares of Disc Medicine during the 3rd quarter worth approximately $38,000. CWM LLC boosted its holdings in Disc Medicine by 213.5% during the second quarter. CWM LLC now owns 1,044 shares of the company's stock worth $55,000 after buying an additional 711 shares in the last quarter. Avanza Fonder AB acquired a new stake in Disc Medicine during the second quarter valued at $57,000. Mirae Asset Global Investments Co. Ltd. grew its position in Disc Medicine by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company's stock valued at $71,000 after buying an additional 181 shares during the period. Finally, Ameritas Investment Partners Inc. increased its holdings in Disc Medicine by 8.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company's stock valued at $133,000 after buying an additional 206 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者最近调整了对该公司的持股。Aster Capital Management DIFC Ltd 在第三季度收购了 Disc Medicine 的新股份，价值约 38,000 美元。CWM LLC 在第二季度将其在 Disc Medicine 的持股增加了 213.5%。CWM LLC 目前持有 1,044 股该公司的股票，价值 55,000 美元，此前在上个季度又购买了 711 股。Avanza Fonder AB 在第二季度收购了 Disc Medicine 的新股份，价值 57,000 美元。Mirae Asset Global Investments Co. Ltd.在第二季度将其在 Disc Medicine 的持股增加了 15.6%。Mirae Asset Global Investments Co. Ltd.目前持有 1,338 股该公司的股票，价值 71,000 美元，此前在此期间又购买了 181 股。最后，Ameritas Investment Partners Inc.在第二季度将其在 Disc Medicine 的持股增加了 8.9%。Ameritas Investment Partners Inc.目前持有 2,515 股该公司的股票，价值 133,000 美元，此前在上个季度又购买了 206 股。当前 83.70% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Disc Medicine</h2>
<div class="lb-trans"><h2>关于 Disc Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.</p>
<div class="lb-trans"><p>Disc Medicine, Inc.及其子公司是一家临床阶段的生物制药公司，专注于发现、开发和商业化针对美国严重血液疾病患者的新治疗方案。该公司已组建了一系列临床和临床前产品候选者，旨在改变与红细胞形成和功能相关的基本生物途径，主要是血红素生物合成和铁稳态。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Disc Medicine</li>
<li>Utilities Stocks Explained – How and Why to Invest in Utilities</li>
<li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>RTX Surges to Record Highs as Defense Orders Explode</li>
<li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li>
<li>Smart Money Is Buying Auto Suppliers, Not Car Brands</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Disc Medicine</li>
<li>公用事业股票解析 – 如何以及为何投资公用事业</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个明智的买入</li>
<li>投资者如何识别并成功交易缺口下跌股票</li>
<li>RTX 因国防订单激增而飙升至历史新高</li>
<li>三大医疗股息股票值得买入和持有</li>
<li>聪明资金正在购买汽车供应商，而不是汽车品牌</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=IRON"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Disc Medicine Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Disc Medicine 吗？</h2>
</div><p>Before you consider Disc Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Disc Medicine 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Disc Medicine 并不在名单上。</p>
</div><p>While Disc Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Disc Medicine 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Disc Medicine（纳斯达克股票代码：IRON）的内部人士 William Jacob Savage 出售了 13,093 股股票